Schering-Plough Reports Financial Results for 2007 Fourth Quarter,...(the ENHANCE trial. (Announced Jan. 25 2...)

-- Announced FDA acceptance for review of the Peg-IFN (peginterferon alfa-

2b) supplemental Biologics License Application, granted Priority Review

status for the adjuvant treatment of patients with Stage III melanoma.

(Announced Jan. 31, 2008)

-- Reported that the antifungal agent NOXAFIL (posaconazole) Oral

Suspension had received an A-1 recommendation (highest rating) for the

prevention of invasive Aspergillus infections in certain high-risk

patients in the latest Treatment of Aspergillosis Clinical Practice

Guidelines of the Infectious Diseases Society of America. (Announced

Jan. 31, 2008)

-- Gained FDA approval of ASMANEX TWISTHALER (mometasone furoate

inhalation powder) for the maintenance treatment of asthma as a

preventive therapy in patients 4 to 11 years of age. (Announced Feb.

4, 2008)

-- Announced final results of a Phase II clinical study showing that

vicriviroc, an investigational CCR5 antagonist, demonstrated potent and

sustained viral suppression through 48 weeks of therapy in treatment-

experienced HIV-infected patients, when administered once-daily as a

single tablet in combination with an optimized ritonavir-boosted

protease inhibitor-containing antiretroviral regimen. (Announced Feb.

6, 2008)

Fourth Quarter 2007 Conference Call and Webcast

Schering-Plough will conduct a conference call today at 8 a.m. (EST) to review the 2007 fourth quarter and full-year results. To listen live to the call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #26183610. A replay of the call will be available beginning later today through 5 p.m. on March 11. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #26183610. A live audio webcast of the conference call also will be availab
'/>"/>